Fate Therapeutics to Participate in Investor Conferences in September 2025.

Fate Therapeutics will participate in the 2025 Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, with presentations and one-on-one meetings scheduled for September 3 and 4. The company's presentations will be webcast live on its website. Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell-derived off-the-shelf cellular immunotherapies.

San Diego, Aug. 25, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company specializing in induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies, has announced its participation in two upcoming investor conferences. The company will present at the 2025 Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference 2025.

At the Wells Fargo Healthcare Conference, scheduled for September 3, 2025, in Boston, Massachusetts, Fate Therapeutics will hold one-on-one meetings with investors. The company will also participate in the Cantor Global Healthcare Conference 2025, taking place on September 4, 2025, in New York, New York. During this conference, Fate Therapeutics will engage in a fireside chat at 10:55 AM ET. Live webcasts of each presentation will be available on the company’s website under the “Events & Presentations” section. The archived webcast will be available shortly after the event [1].

Fate Therapeutics is dedicated to developing a pipeline of iPSC-derived cellular immunotherapies. The company's proprietary iPSC product platform has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed to incorporate novel synthetic controls of cell function and deliver multiple therapeutic mechanisms to patients [2].

The increasing demand for iPSC-based solutions is driven by their potential in drug discovery, regenerative medicine, and disease modeling. The global iPSC production market size was valued at approximately USD 1.75 billion in 2024 and is expected to reach USD 1.92 billion in 2025, with a projected value of around USD 4.34 billion by 2034, at a CAGR of 9.5% [2].

Key players in the iPSC market include Lonza, Axol Bioscience Ltd., Evotec, Hitachi Ltd., REPROCELL Inc., Merck KGaA, Fate Therapeutics, Thermo Fisher Scientific, StemCellsFactory III, Applied StemCell Inc., FUJIFILM Cellular Dynamics Inc., Ushio Inc., QHP Capital, Accelerated Biosciences, Aspen Neuroscience Inc., Cynata Therapeutics, Ncardia, Pluristyx, STEMCELL Technologies, Takara Bio Inc, and others.

References:

[1] https://www.marketscreener.com/news/fate-therapeutics-to-present-at-upcoming-investor-conferences-ce7c50d8d889f526
[2] https://finance.yahoo.com/news/latest-global-induced-pluripotent-stem-193000100.html